acarbose; diabète de type 2; prévention; orlistat; obésité; metformine; angiotensine
Abstract :
[fr] L’augmentation rapide de la prévalence du diabète de type 2 impose la mise en place de stratégies de prévention. Outre les mesures hygiéno-diététiques, essentielles, diverses approches pharmacologiques ont apporté récemment la preuve d’une certaine efficacité chez les sujets à risque de par la présence d’un excès pondéral et/ou d’une diminution de la tolérance au glucose. C’est le cas de plusieurs antidiabétiques oraux comme la metformine, l’acarbose ou encore la troglitazone. C’est également le cas de médicaments anti-obésité comme l’orlistat et, peut-être aussi, la sibutramine. L’inhibition du système rénine-angiotensine par un inhibiteur de l’enzyme de conversion ou par un antagoniste sélectif des récepteurs AT1 peut aussi, outre protéger contre les complications cardiovasculaires, prévenir l’apparition d’un diabète de type 2. Enfin, le rôle des médicaments hypolipidémiants reste controversé. De nouvelles études prospectives sont en cours pour confirmer ces résultats.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
SCHEEN, André ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
PAQUOT, Nicolas ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
LETIEXHE, Michel ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
JANDRAIN, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Language :
French
Title :
Approches pharmacologiques de prévention du diabète de type 2.
WHO Study Group. Prevention of diabetes mellitus: Report of WHO study group. WHO Tech Rep Ser 1994; 844: 1-100.
Donelly R, Garber A (Eds). Progression of type 2 diabetes - inevitable or preventable? Diab Obes Metab 2001; 3 (Suppl. 1): S1-S43.
American Diabetes Association and National Institute of Diabetes, Digestive and Kidney Disease. The prevention or delay of type 2 diabetes (Position Statement). Diabetes Care 2002; 25: 742-9.
Tuomilehto J, Lindström J. Ericksson JG, et al for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50.
Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
Scheen AJ. Drug treatment of noninsulin-dependent diabetes mellitus in the 1990s: Achievements and future developments. Drugs 1997; 54: 355-68.
Groop LC. Sulfonylureas and NIDDM. Diabetes Care 1992; 15: 737-54.
Sartor G, Schersten B, Carlström S, et al. Ten-year follow-up of subjects with impaired glucose tolerance. Prevention of diabetes by tolbutamide and diet regulation. Diabetes 1980; 29: 41-9.
Cusi K, DeFronzo RA. Metformin: A review of its metabolic effects. Diabetes Rev 1998; 6: 89-131.
Scheen AJ, Paquot N, Letiexhe MR, Lefèbvre PJ. A propos de quelques utilisations non conventionnelles de la metformine. Med Hyg 1997; 55: 1492-4.
Scheen AJ, Letiexhe MR, Lefèbvre PJ. Short administration of metformin improves insulin sensitivity in obese android subjects with impaired glucose tolerance. Diabetic Med 1995; 12: 985-9.
Scheen AJ, Jandrain B, Paquot N. Contrôle pharmacologique de l'hyperglycémie post-prandiale. Med Hyg 2001; 59: 1619-24.
Scheen AJ. Place de l'acarbose dans le traitement du diabète sucré. Diab Metab 1998; 24: 385-90.
Chiasson J-L, Josse RG, Gomis R, et al for the STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-7.
Scheen AJ, Paquot N, Letiexhe MR, Lefèbvre PJ. Les thiazolidinediones, In: Joumées de diabétologie de l'Hôtel-Dieu. Paris: Flammarion, Médecine-Sciences, 1999; 213-29.
Buchanan T, Xiang A, Peters R, et al. Prevention of type 2 diabetes by treatment of insulin resistance: Comparison of early vs. late intervention in the TRIPOD study (Abstract). Diabetes 2002; 51 (Suppl. 2): A35.
Owens DR. Repaglinide - prandial glucose regulator: A new class of oral antidiabetic drug. Diabetic Med 1998; 15 (Suppl. 4): S28-S36.
The NAVIGATOR Trial Steering Committee. Nateglinide and valsartan in impaired glucose tolerance outcomes research. Rationale and design of the NAVIGATOR trial (Abstract). Diabetes 2002; 51 (Suppl. 2): A116.
Scheen AJ. Obesity and diabetes. In: The management of obesity and related disorders (Kopelman PG, Ed.). London: Martin Dunitz Ltd, 2001: 11-44.
Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes 1992; 16: 397-415.
Scheen AJ, Paolisso G, Salvatore T, Lefèbvre PJ. Improvement of insulin-induced glucose disposal in obese patients with NIDDM after one-week treatment with d-fenfluramine. Diabetes Care 1991; 14: 325-32.
McNeely W, Benfield P. Orlistat. Drugs 1998; 56: 241-9.
McNeely W, Goa KL. Sibutramine. A review of its contribution in the management of obesity. Drugs 1998; 56: 1093-124.
Scheen AJ, Lefèbvre PJ. Antiobesity pharmacotherapy in the management of type 2 diabetes. Diabetes/Metab Res Rev 2000; 16: 114-24.
Scheen AJ. Current management strategies for coexisting diabetes mellitus and obesity. Drugs 2002; 62: in press.
Keating GM, Jarvis B. Orlistat. In the prevention and treatment of type 2 diabetes mellitus. Drugs 2001; 61: 2107-19.
Rosenfalck AM, Hendel H, Rsamussen MH, et al. Minor long-term changes in weight have beneficial effects on insulin sensitivity and beta-cell function in obese subjects. Diab Obesity Metab 2002; 4: 19-28.
Heymsfield SB, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160: 1321-6.
Van Gaal LF, Pfeiffer FW. The importance of obesity in diabetes and its treatment with sibutramine. Int J Obes Relat Metab Disord 2001; 25 (Suppl. 4): S24-8.
Paquot N, Scheen AJ, Lefèbvre PJ. Contribution hémodynamique à l'insulinorésistance: du concept physiopathologique aux perspectives thérapeutiques. Med Hyg 1995; 53: 1633-7.
Scheen AJ. Prévention de l'apparition du diabète de type 2 par l'inhibition du système rénine-angiotensine. Rev Med Liège 2002; 57: 449-52.
Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-6.
Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA 2001; 286: 1882-5.
Dahlöf B, Devereux RB, Kjeldsen SE, et al, for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003.
Hu FB, van Dam RM, Liu S. Diet and risk of type 2 diabetes: The role of types of fat and carbohydrate. Diabetologia 2001; 44: 805-17.
Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 45: 3-10.
Freeman D, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357-62.
Heart protection study collaborative group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebocontrolled trial. Lancet 2002; 360: 7-22.
